Clinical-alimentary tractA prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator
Section snippets
Study population and protocol
Between 1996 and 2001, female patients between the ages of 18 and 70 years with a functional bowel disorder were enrolled at the University of North Carolina and the University of Toronto to participate in a treatment trial. 4 Before randomization and at the end of the 3-month treatment period either with desipramine or pill placebo or with cognitive-behavioral treatment or education, patients filled out 2 weeks of daily diary cards and then underwent clinical and physiologic assessments. After
Study population
At baseline, there were 317 women with IBS. These patients were subcategorized as having IBS-D (35.6%), IBS-M (neither IBS-D nor IBS-C; 30.6%), or IBS-C (33.8%) using Rome II definitions. The mean age was 38.6 years, 84.9% were white, the mean education level was 14.9 years, and 49.2% were married. There were no demographic differences between subtypes of IBS, except that women with IBS-M were about 2 years younger than women with IBS-D or IBS-C (P = .04).
Baseline comparisons of clinical variables
Table 1 compares the 3 IBS subtypes at
Discussion
IBS is defined as abdominal pain or discomfort associated with altered bowel habit (ie, diarrhea, constipation, or both). 1, 2, 3 In recent years, IBS has been subcategorized into either IBS-D or IBS-C using definitions from the Rome II criteria. 2, 3 The remaining group with Rome II IBS (ie, non–IBS-D, non–IBS-C) is best considered as IBS-M, because this is a heterogeneous group consisting of individuals having symptoms of diarrhea and constipation but not meeting Rome II criteria for either
References (15)
- et al.
AGA technical review on irritable bowel syndrome
Gastroenterology
(2002) - et al.
Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders
Gastroenterology
(2003) The McGill Pain Questionnairemajor properties and scoring methods
Pain
(1975)- et al.
Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome
Gastroenterol Clin Biol
(2004) - et al.
C. Functional bowel disorders and D. functional abdominal pain
- et al.
Functional bowel disorders and functional abdominal pain
Gut
(1999) - et al.
Relation between stool form on a seven point scale and symptoms of urgency, straining, and incomplete evacuation: a new way of looking at irritable bowel syndrome
Gut
(1989)
Cited by (172)
Quantum chemical, spectroscopic and molecular docking studies on methyl 2-chloro-6-methyl pyridine-4-carboxylate: A potential inhibitor for irritable bowel syndrome
2023, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyIrritable bowel syndrome in adults: Prevalence and risk factors
2022, Annals of Medicine and SurgeryMaking a Confident Diagnosis of Irritable Bowel Syndrome
2021, Gastroenterology Clinics of North AmericaCitation Excerpt :These classifications, however, are subject to recall bias and reflect symptoms over a relatively fixed historical period, and switching from one IBS subtype to another over time has been widely reported.19 In a prospective assessment of abnormal bowel habits of women with IBS, Drossman and colleagues20 found that more than 75% moved to 1 of the other subtypes at least once over a 1-year period. Further complicating the extrapolation of the Rome criteria to routine primary care and GI clinical practice is the fact that IBS exists on a continuum with other disorders of gut-brain interaction, such as chronic idiopathic constipation, functional diarrhea, and functional bloating.21
Transplanting Microbes for Irritable Bowels or Irritated Microbes or Both?
2021, GastroenterologyGlobal prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis
2020, The Lancet Gastroenterology and HepatologyDifferences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption
2020, GastroenterologyCitation Excerpt :However, we were able to identify a subset of patients with IBS-D and IBS-M with BAM who were distinguishable by a metabolomic signature. Transit time (reflected by Bristol Stool Score) is a major covariate with microbiome composition,47 but the tendency for patients with IBS to alternate between the mixed, constipation, and diarrhea subtypes48 may mask or average out microbiota associations with transit time and may explain the modest microbiota alterations previously observed in IBS.12 Regardless, all 3 subtypes can be distinguished from control individuals by a common fecal microbiome signature based on metagenomic species analysis.
Supported by National Institutes of Health grant RO1DK49334 and Novartis Pharmaceuticals.